This is a news story, published by CNBC, that relates primarily to Eli Lilly news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
revenue expectations. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Eli Lilly news, profit guidance news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
earningsCNBC
•
83% Informative
Eli Lilly reported third-quarter adjusted profit and revenue that missed expectations, sending its stock tumbling roughly 10% .
The drugmaker now expects full-year adjusted earnings of between $13.02 to $14.52 per share, down from $ 16.60 per share.
Eli Lilly also lowered the high-end of its revenue outlook for the year and now expects sales of $45.4 billion and $46 billion .
VR Score
86
Informative language
89
Neutral language
25
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links